Comparison

Gossypol European Partner

Item no. HY-13407-100mg
Manufacturer MedChem Express
CASRN 303-45-7
Amount 100 mg
Quantity options 100 mg 10 mM/1 mL 200 mg 500 mg 50 mg
Category
Type Inhibitors
Specific against other
Purity 99.67
Citations [1]Oliver CL, et al. In vitro effects of the BH3 mimetic, (-)-Gossypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res. 2004 Nov 15;10(22):7757-63.
Microb Pathog. 2024 Sep 21:106960.|Transbound Emerg Dis. 2023 Nov 11.|Clin Transl Med. 2021 Jun;11(6):e467.|Patent. US20220162561A1.|Nat Commun. 2023 Jun 10;14(1):3445.|Patent. US20220162561A1.
Smiles O=CC1=C(O)C(O)=C(C(C)C)C2=CC(C)=C(C3=C(C)C=C4C(C(C)C)=C(O)C(O)=C(C=O)C4=C3O)C(O)=C12
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias BL 193
Shipping Condition Room temperature
Available
Manufacturer - Type
Natural Products
Manufacturer - Applications
Cancer-programmed cell death
Manufacturer - Targets
Bcl-2 Family
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Molecular Weight
518.55
Product Description
Gossypol binds to Bcl-xL protein and Bcl-2 protein with Kis of 0.5-0.6 μM and 0.2-0.3 mM, respectively.
Manufacturer - Research Area
Cancer
Solubility
DMSO: 33.33 mg/mL (ultrasonic)
Manufacturer - Pathway
Apoptosis
Isoform
Bcl-2; Bcl-xL
Clinical information
Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 100 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close